BackProcter & Gamble Health Limited Overview

Procter & Gamble Health Limited EBIT

Track Procter & Gamble Health Limited's EBIT ($5.2B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

$1.46B
↑ 22.79% YoY

As of Sep 30, 2026

Annual EBIT (TTM)

$5.18B
↑ 30.3% YoY

Trailing 12 months ending Sep 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Procter & Gamble Health Limited (PGHL.NS) FAQ

As of the most recent data (September 2026), PGHL.NS shows a EBIT of $5.2B. That compares with $4B in the prior-year period — up 30.3% year over year. That is below the sector sector average of $2.4T. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, PGHL.NS's EBIT is now $5.2B (was $4B) — a 30.3% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Procter & Gamble Health Limited is outperforming or lagging.

The its sector sector average EBIT is about $2.4T. Procter & Gamble Health Limited is at $5.2B, which is lower that average. That is roughly 99.8% below the sector mean. Use the comparison chart on this page to see how PGHL.NS stacks up against individual peers as well.

Tracking PGHL.NS's ebit over time shows whether Procter & Gamble Health Limited is scaling, shrinking, or reshaping that part of the business. The current reading is $5.2B That compares with $4B in the prior-year period — up 30.3% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this ebit page, Stockcircle has Procter & Gamble Health Limited's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $5.2B) with ownership activity and broader fundamentals.